Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older by Nabhan, Chadi, Rundhaugen, Lynn M., Riley, Mary B., Rademaker, Alfred, Boehlke, Larry, Jatoi, Mashal, Tallman, Martin S.

Get full text

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old by Parmar, Simrit, Rundhaugen, Lynn M, Boehlke, Larry, Riley, MaryBeth, Nabhan, Chadi, Raji, Adekunle, Frater, John L, Tallman, Martin S

Get full text

Structure-function relationships of the dietary anticarcinogen ellagic acid by Barch, David H., Rundhaugen, Lynn M., Stoner, Gary D., Pillay, N.Sokalingum, Rosche, William A.

Get full text

Ellagic acid induces transcription of the rat glutathione S-transferase-Ya gene by Barch, David H., Rundhaugen, Lynn M., Pillay, N.Sokalingum

Get full text

Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene by Barch, David H., Rundhaugen, Lynn M.

Get full text

Nonepileptic seizures treatment workshop summary by LaFrance, W. Curt, Alper, Kenneth, Babcock, Debra, Barry, John J., Benbadis, Selim, Caplan, Rochelle, Gates, John, Jacobs, Margaret, Kanner, Andres, Martin, Roy, Rundhaugen, Lynn, Stewart, Randy, Vert, Christina

Get full text

Changes in Finances, Insurance, Employment, and Lifestyle Among Persons Diagnosed with Hairy Cell Leukemia by Hounshell, Jennie, Tomori, Cecilia, Newlin, Rebecca, Knox, Kirstin, Rundhaugen, Lynn, Tallman, Martin, Bennett, Charles

Get full text